Treatment Delayed is Treatment Denied.

J Am Acad Psychiatry Law

Dr. Biswas is the Director of Psychiatry, Law and Society, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA and a forensic psychiatrist in the Department of Psychiatry, Bridgewater State Hospital, MA. Dr. Drogin is a lecturer, Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Dr. Gutheil is Professor of Psychiatry, Department of Psychiatry, Beth Israel Deaconess Medical Center and the Massachusetts Mental Health Center, Harvard Medical School, Boston, MA.

Published: December 2018

The past few decades have witnessed the steady development of a mental health jurisprudence dedicated to the preservation of human rights. Self-determination and personal autonomy are critical aspects of this perspective, pervading every facet of institutional psychiatric care. Of considerable concern, however, are those cases in which rote procedural approaches produce unintended consequences for the very persons such maneuvers were designed to protect. Delays-inherent in court-based procedures-may ironically lead to an acute illness becoming chronic, and to a single bout of inpatient services being transformed into a lifetime of revolving-door psychiatric admissions. This discussion is not about lawyers or lawyering; rather, it is about the proposition that a better system can and should be devised for advocates who must make do with the options they are dealt. A particularly problematic example is the "Rogers Guardianship" model currently prevalent in Massachusetts. Laws that effectively place on counsel and courts the challenge of second-guessing medical treatment decisions-with minimal latitude for counsel to exercise measured professional judgment-will inevitably generate, and empirically do generate, a degree of delay that ironically deprives patients of the liberation from illness that is the common goal of all stakeholders. Possible solutions to these difficulties are also suggested.

Download full-text PDF

Source
http://dx.doi.org/10.29158/JAAPL.003786-18DOI Listing

Publication Analysis

Top Keywords

treatment delayed
4
delayed treatment
4
treatment denied
4
denied decades
4
decades witnessed
4
witnessed steady
4
steady development
4
development mental
4
mental health
4
health jurisprudence
4

Similar Publications

Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel.

View Article and Find Full Text PDF

Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS).

Methods: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies.

View Article and Find Full Text PDF

HIV-1 envelope broadly neutralizing antibodies represent a promising component of HIV-1 cure strategies. To evaluate the therapeutic efficacy of combination monoclonal antibodies (mAbs) in a rigorous nonhuman primate model, we tested different combinations of simian immunodeficiency virus (SIV) neutralizing mAbs in SIVmac251-infected rhesus macaques. Antiretroviral therapy-suppressed animals received anti-SIV mAbs targeting multiple Env epitopes spanning analytical treatment interruption (ATI) in 3 groups (n = 7 each): i) no mAb; ii) 4-mAb combination; and iii) 2-mAb combination.

View Article and Find Full Text PDF

Early repair of flexor tendon injuries is ideal, but delays are common. We studied the outcomes of flexor tendon repairs delayed from 5 days to 6 months and carried out under wide-awake local anaesthesia with no tourniquet (WALANT). Twenty-four patients (29 fingers) who underwent primary flexor tendon repair on zone II using a four- to six-strand core suture technique, followed by controlled early active motion therapy.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the biological changes in rabbit corneas caused by two light-activated corneal stiffening methods: riboflavin with UVA and WST11 with NIR.
  • Differentially expressed proteins were identified following treatments, showing RF-D/UVA affected cell metabolism and keratocyte differentiation, while WST-D/NIR influenced extracellular matrix regulation.
  • The findings reveal a metabolic shift towards glycolysis in RF-D/UVA treated corneas compared to normal respiration in WST-D/NIR treated corneas, highlighting the distinct biological effects of each treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!